LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) — London Research & Pharmaceuticals has recently unveiled groundbreaking data on their lead compound, LRP-661, also known as Cannabidiol sulphate (CBDS), at the esteemed Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami. The presentation showcased CBDS’s superior safety, efficacy, bioavailability, and predictable PK parameters compared to existing oral cannabidiol formulations.
The data revealed that CBDS outperforms the current sesame oil-based oral solution of cannabidiol in terms of gastrointestinal tolerability, weight preservation, and absence of liver or renal toxicity, paving the way for potential advancements in epilepsy treatment. Notable expert Dr. Henrik Klitgaard commended CBDS as a promising new formulation that could revolutionize the landscape of epilepsy medication, particularly enhancing tolerability and compliance, leading to improved clinical outcomes.
Following the positive reception at the ETDD XVII conference, London Research & Pharmaceuticals is enthusiastic about the clinical and commercial prospects of CBDS and aims to progress swiftly through a comprehensive clinical program. The company is preparing to engage with the FDA for a pre-IND meeting in the second quarter of 2024 to initiate the regulatory and clinical development process for LRP-661 (CBDS) effectively.
In addition to CBDS, London Research & Pharmaceuticals is actively developing a diverse portfolio of compounds targeting various therapeutic areas, including inflammation, infectious diseases, oncology, and psychiatric disorders, underscoring their commitment to innovation in the pharmaceutical field. The company remains open to collaboration opportunities to further advance their proprietary compounds.
With a strong emphasis on research and development excellence, London Research & Pharmaceuticals continues to strive for impactful contributions to the medical community, positioning themselves as key players in the pharmaceutical industry.
For more information, please visit www.londonresearch.ca.
